| Literature DB >> 27775559 |
Igor V Ukrainets1, Lidiya A Petrushova2, Svitlana V Shishkina3,4, Lina A Grinevich5, Galina Sim6.
Abstract
In order to obtain and then test pharmocologically any possible conformers of the new feasible analgesic N-benzyl-4-hydroxy-1-methyl-2,2-dioxo-1H-2λ⁶,1-benzothiazine-3-carboxamide, itsEntities:
Keywords: 4-hydroxy-2,2-dioxo-1H-2λ6,1-benzothiazine-3-carboxamide; analgesic activity; conformation; conformer; crystal structure; solvate
Year: 2016 PMID: 27775559 PMCID: PMC5198029 DOI: 10.3390/scipharm84040705
Source DB: PubMed Journal: Sci Pharm ISSN: 0036-8709
Figure 1Pseudo-enantiomeric conformers of N-benzyl-4-hydroxy-1-methyl-2,2-dioxo-1H-2λ6,1-benzothiazine-3-carboxamide (1) [13].
Scheme 1Synthesis of sodium-3-benzylaminocarbonyl-1-methyl-2,2-dioxo-1H-2λ6,1-benzothiazin-4-olate solvates 2 and 3.
Figure 2The molecular structure of sodium salt methanol monosolvate (2) with numeration of atoms which coordinate Na cation. The hydrogen atoms are omitted for clarity.
Figure 3The molecular structure of sodium salt monohydrate (3) with numeration of anion atoms of symmetry independent part of complex. The hydrogen atoms are omitted for clarity.
Figure 4Highly active (A) and low active (B) conformers of benzylamide (1) (experimental data); highly active (C) and low active (D) conformers of sodium salt methanol solvate (2) (presumably); low-active conformer (E) of sodium salt hydrate (3) (experimental data). Sodium atoms and molecules of the solvents in the conformers (C–E) are not specified.
Figure 5Infinite chain (1D polymer) formed by sodium salt monohydrate (3) along [100] crystallographic direction in the crystal phase. The hydrogen atoms are omitted for clarity.
Figure 6Layer (2D polymer) formed by sodium salt methanol monosolvate (2) in the crystal phase. The hydrogen atoms are omitted for clarity.
The analgesic activity of pseudo-enantiomeric forms of benzylamide (1), solvates of sodium salts 2 and 3, and reference drugs.
| Entry | Product | Conformer | Latent Period in 1 h after Introduction of the Compounds (s) a | Change of the Latent Period, Compared to Control (%) |
|---|---|---|---|---|
| 1 | 15.98 ± 0.85 | +111.9 | ||
| 2 | 9.88 ± 0.72 | +31.1 | ||
| 3 | 12.27 ± 0.81 | +62.7 | ||
| 4 | 9.86 ± 0.70 | +30.8 | ||
| 5 | Meloxicam | - | 11.27 ± 0.83 | +49.5 |
| 6 | Piroxicam | - | 9.45 ± 0.74 | +25.3 |
| 7 | Control | - | 7.54 ± 0.82 | - |
a All results from biological tests were analyzed statistically using Student’s t-test. Effects were regarded as statistically significant at p ≤ 0.05.